APUA Newsletter Vol. 34. No. 1
"Perspectives on Preserving and Expanding Antimicrobial Options"


APUA Voices Support for Global Industry Declaration Tackling Antimicrobial Resistance
The Alliance for the Prudent Use of Antibiotics (APUA) applauds the global pharmaceutical, biotechnology and diagnostics industry declaration on combating antimicrobial resistance.

“Marking a major step in the global battle fighting the problems of antimicrobial resistance, the statement sets out for the first time how governments and industry need to work together to support sustained investment in the new products needed to beat the challenges of rising drug resistance,” said Dr. Stuart B. Levy, CEO of the Alliance for the Prudent Use of Antibiotics. 

Launched at the World Economic Forum in Davos, Switzerland, this declaration formally cites the encouraging news of more than 85 international companies and nine industry associations across 18 countriesworking together to take collective action to address the resistance problem.


The Alliance for the Prudent Use of Antibiotics is pleased to honor Kevin Outterson, J.D., LL.M., professor at the Boston University School of Law and Boston University School of Public Health, as the recipient of our 2015 Leadership Award.

Professor Outterson, the N. Pike Scholar in Health and Disability Law and co-director of BU's health law program, is the author of groundbreaking models to address the economic challenge of developing new antibiotics. Together with his scholarship and testimony before the United States Congress, he elevates the issues of antimicrobial resistance to a new level, catalyzing access to effective treatment of bacterial infections for all.

"We recognize Professor Outterson as a thought leader in the worldwide effort to contain antibiotic resistance," said APUA President Stuart B. Levy. "His intellectual commitment to the economic realities of developing new drugs that affect the global aspects and consequences of antibacterial resistance alter our thinking about answers to these complex problems."

Our warmest congratulations to Professor Outterson.

In case you missed it, our latest webinar is now available for streaming.
Click the video below




APUA President Levy attends "White House Forum on Antibiotic Stewardship"

The summit, the first of its kind, was attended by 150+ leaders of the health, food, and agriculture industries on June 2, 2015. The event was buttressed by the signing of a Presidential Memorandum that creates Federal preference for meat and poultry that are produced with responsible antibiotic use. The various attendees made commitments to abide by the standards set forth by the recently-published National Action Plan for Combating Antibiotic-Resistance Bacteria. Read APUA's commitment here


Antibiotics are humanity's key defense against disease-causing microbes. The growing prevalence of antibiotic resistance threatens a future where these drugs can no longer cure infections and killer epidemics run rampant. The Alliance for the Prudent Use of Antibiotics (APUA) has been the leading global non-governmental organization fighting to preserve the effectiveness of antimicrobial drugs since 1981. With affiliated chapters in over 66 developed and developing countries, we conduct research, education and advocacy programs to control antimicrobial resistance and ensure access to effective antibiotics for current and future generations. For more information on antibiotic resistance research, visit our partner lab at the Center for Adaptation Genetics and Drug Resistance.

Antibiotic Resistance
in the News

WHO Worldwide Country Situational Analysis: Response to Antimicrobial Resistance

The National Action Plan for Combating Antibiotic-Resistant Bacteria, 2015

2014 PCAST Report on 
Combating Antimicrobial Resistance






Public Health AdvocacyGlobal Research and Survellience

Consumer and Practioner ResourcesAPUA Chapters

"Antibiotics are uniquely societal drugs because individual use affects others in the community and environment.  Better stewardship, incentives, and establishment of a special regulatory category will improve how they are used, marketed, and developed through incentives to industry."

Stuart B. Levy, M.D.
President of APUA, professor at Tufts University School of Medicine

From the IOM 25th Anniversary Symposium (1996) and The Antibiotic Paradox (2002)

2014 Alliance for the Prudent Use of Antibiotics | 136 Harrison Ave, M&V Suite 811, Boston, MA, 02111 | Tel 617.636.0966 | apua@tufts.eduHome | Search | Contact Us